Role of IL-10 in allergen-specific immunotherapy and normal response to allergens

Microbes and Infection

Volumn 3, Issue 11, 2001, Pages 891-898

  Akdis, Cezmi A ^a   Blaser, Kurt ^a  

^a SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Anergy; CD28; Interleukin 10; Specific immunotherapy; Tolerance

Indexed keywords

ALLERGEN; ANTIBODY; BEE VENOM; CD28 ANTIGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PHOSPHATIDYLINOSITOL 3 KINASE; TYROSINE; UNCLASSIFIED DRUG;

ALLERGY; ANTIGEN SPECIFICITY; CELL ACTIVATION; CELL PROLIFERATION; CELL SPECIFICITY; CLONAL ANERGY; CYTOKINE PRODUCTION; ENZYME BINDING; EOSINOPHIL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0034846513     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(01)01449-6     Document Type: Review

References (76)

1. The expanding universe of T-cell subsets: Th1, Th2 and more
2. Lymphokine production by human T cells in disease states
3. Lymphocyte responses and cytokines
4. WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
5. Position paper: Immunotherapy with hymenoptera venoms
6. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety
7. Grass pollen immunotherapy: Efficacy and safety during a 4 year follow-up study
8. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergic drugs
9. Long-term clinical efficacy of grass-pollen immunotherapy
10. Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass
11. Seasonal asthma in northern California: Allergic causes and efficacy of immunotherapy
12. 2 antibodies
13. Nasal challenge with ragweed in hay fever patients: Effect of immunotherapy
14. The effect of immunotherapy on bronchial hyper-responsiveness and eosinophil cationic protein in pollen allergic patients
15. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro
16. Role of IL-10 in specific immunotherapy
17. IL-10 induced anergy in peripheral T-cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy
18. Differential regulation of human T-cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants
19. 2 induces specific T-cell anergy in bee sting allergic patients
20. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen stimulated T-cell cultures
21. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects
22. Effects of peptide therapy on ex vivo T-cell responses
23. Glucocorticoids inhibit human antigen-specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro
24. 2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and non-specific activation of T and B cells
25. 2-specific T-cell clones from human allergic and non-allergic individuals: Cytokine patterns change in response to the antigen concentration
26. 2
27. The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific Th cells
28. 2
29. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding
30. lck and ZAP-70 tyrosine kinase activities
31. Allergen immunotherapy decreases interleukin 4 production in CD4 T cells from allergic individuals
32. Immunological changes associated with immunotherapy
33. Ragweed immunotherapy decreases T cell reactivity to recombinant Amb A I.1
34. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
35. Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I
36. Treatment of cat allergy with T cell reactive peptides
37. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions
38. Nasal immunotherapy in weed-induced allergic rhinitis
39. Effect of preseasonal enzyme potentiated desensitization on plasma IL-6 and IL-10 of grass pollen-sensitive asthmatic children
40. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones
41. IL-10 inhibits cytokine production by activated macrophages
42. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
43. Differential effects of interleukin-4 and -10 on interleukin-2 induced interferon-γ synthesis and lymphokine activated killer activity
44. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production
45. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice
46. Modulation by IL-10 of antigen-induced IL-5 generation, and CD4+ T lymphocyte and eosinophil infiltration into the mouse peritoneal cavity
47. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10
48. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage co-stimulatory function
49. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin
50. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells
51. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10
52. Induction of hapten-specific tolerance by interleukin 10 in vivo
53. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells
54. Maintanence of clonal anergy by endogeneously produced IL-10
55. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
56. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils
57. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma
58. Glucocorticoids
59. Interleukin 4 is an essential factor for in vitro clonal growth of murine connective tissue-type mast cells
60. Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family
61. Regulation of human basophil mediator release by cytokines. I. Interaction with anti-inflammatory steroids
62. Interleukin (IL)-10 Inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells
63. IL-10: A potential therapy for allergic inflammation?
64. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils
65. CD40 expression by human peripheral blood eosinophils
66. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway
67. PI 3-kinase: Structural and functional analysis of intersubunit interactions
68. PI3-kinase: A pivotal pathway in T-cell activation?
69. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif
70. The genomic organization of the CD28 gene: Implications for the regulation of CD28 mRNA expression and heterogeneity
71. Fyn regulate CD28 binding to phosphatidiylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: Implications for T-cell costimulation
72. IL-10 induces the tyrosine phosphorylation of Tyk2 and Jak1 and the differential assembly of STAT1α and STAT3 complexes in human T cells and monocytes
73. Functional regions of the mouse interleukin-10 receptor cytoplasmic domain
74. Interleukin-10 inhibits expression of both interferon α and interferon γ-induced genes by suppressing tyrosine phosphorylation of STAT1
75. Identification and functional characterization of a second chain of the interleukin-10 receptor complex
76. Molecular basis of T cell inactivation by CTLA-4